SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Versant Ventures VII GP, L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 1650 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/22/2026	3. Issuer Name and Ticker or Trading Symbol Lycia Therapeutics, Inc. [ LYCA ] Foreign Trading Symbol
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	(1)	Common Stock	25,390,410	(1)	I	See Footnote(2)
Series B Preferred Stock	(1)	(1)	Common Stock	6,284,597	(1)	I	See Footnote(3)

1. Name and Address of Reporting Person* Versant Ventures VII GP, L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 1650 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)

1. Name and Address of Reporting Person* Versant Venture Capital VII, L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 1650 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)

1. Name and Address of Reporting Person* Versant Ventures VII GP-GP, LLC (Last) (First) (Middle) ONE SANSOME STREET, SUITE 1650 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)

1. Name and Address of Reporting Person* Versant Vantage II, L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 1650 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)

1. Name and Address of Reporting Person* Versant Vantage II GP, L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 1650 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)

1. Name and Address of Reporting Person* Versant Vantage II GP-GP, LLC (Last) (First) (Middle) ONE SANSOME STREET, SUITE 1650 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)

Explanation of Responses:

1. Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into Common Stock on a one-for-0.221793422 basis at the option of the holder, and will convert automatically upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

2. The shares are held directly by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP, L.P. ("VV VII GP") is the general partner of VVC VII, and Versant Ventures VII GP-GP, LLC ("VV VII GP-GP") is the general partner of VV VII GP. Each of VV VII GP-GP and VV VII GP disclaims beneficial ownership of the shares held by VVC VII, except to the extent of their respective pecuniary interests therein.

3. The shares are held directly by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP, L.P. ("VV II GP") is the general partner of VV II, and Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the general partner of VV II GP. Each of VV II GP-GP and VV II GP disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein.

	Versant Venture Capital VII, L.P. By: Versant Ventures VII GP, L.P. Its: General Partner By: Versant Ventures VII GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer	10/22/2026
	Versant Ventures VII GP, L.P., By: Versant Ventures VII GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer	10/22/2026
	Versant Ventures VII GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer	10/22/2026
	Versant Vantage II, L.P. By: Versant Vantage II GP, L.P. Its: General Partner By: Versant Vantage II GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer	10/22/2026
	Versant Vantage II GP, L.P., By: Versant Vantage II GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer	10/22/2026
	Versant Vantage II GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.